By Jennifer Ahlstrom | Posted - Nov 1st, 2019





Lenalidomide Can Delay Bone and Organ Damage for Smoldering Myeloma Patients

In the largest ever study of smoldering myeloma patients from 13 major myeloma facilities, lenalidomide was found to delay disease progression, and helped prevent bone damage and end organ damage. The study was run by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.

"Curative" treatment strategies are also being evaluated for high risk smoldering myeloma patients. Such a study is the ECOG-ACRIN study, comparing daratumumab, lenalidomide, and dexamethasone (with the goal of a cure) vs. lenalidomide plus dexamethasone (with the goal of prevention). The future results from this study can be compared to this current study and will provide clarity on the best long-term strategy for high risk smoldering myeloma. While we are waiting on those results, lead study author Vincent Rajkumar, MD of the Mayo Clinic said:


Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .